All blog posts
Total 19 results for
Showing 12 out of 19 results
29 outubro 2025
"Pay-for-delay" continued: Court of Justice rules on appeal in Teva-Cephalon
01 novembro 2024
EU Commission fines Teva €462.6 million for misuse of divisional patents and disparagement campaign
29 julho 2024
Commission investigation into anticompetitive disparagement ends with commitments
24 junho 2024
Overview of EU regulatory and competition law in the Pharma sector
19 fevereiro 2024
Five Years of Activity in a Priority Sector: The European Commission's Report on Competition Enforcement in the Pharmaceutical Sector (2018-2022)
06 dezembro 2023
Competition law and biosimilars: Time for a new approach or not yet?
31 outubro 2023
Another chapter in the "pay for delay" saga: General Court rules on the Teva-Cephalon settlement agreement
15 junho 2023
Overview of EU and South African regulatory and competition law in the Pharma sector
09 fevereiro 2023
Competition law developments in the pharma sector – 2022 round-up and what to expect in 2023
23 novembro 2022
SANCTION IMPOSED BY THE SPANISH COMPETITION AUTHORITY ON A PHARMA COMPANY FOR MISUSING LITIGATION STRATEGIES REGARDING PATENTS
11 outubro 2022
Update on the Teva Copaxone EU case. The EU Commission issues a Statement of Objections against Teva over alleged anti-competitive conduct consisting of misuse of divisional patents and a disparagement campaign against its closest competitor
09 fevereiro 2022
Competition law in the pharma sector – Developments and what’s to come in 2022
Showing 12 out of 19 results
View moreKey contacts
Kyriakos Fountoukakos
Managing Partner, Competition/Antitrust, Regulation and Trade, Brussels
Veronica Roberts
Partner, Head of Competition/Antitrust, Regulation and Trade, UK, London
Linda Evans
Partner, Head of Competition/Antitrust, Regulation and Trade, Australia, Sydney
Adelaide Luke
Partner, Head of Competition, Asia, Hong Kong
Jean Meijer
Managing Partner, Johannesburg Office, Johannesburg
Kristien Geeurickx
Knowledge Counsel, London